TuHURA Biosciences (HURA) Cash & Equivalents (2010 - 2026)

TuHURA Biosciences' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $6.3 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 1.29% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $6.3 million (up 1.29% YoY), while the FY2025 annual figure was $3.6 million, down 71.4% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $6.3 million, up from $3.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $12.7 million in Q4 2024, with the low at $216000.0 in Q3 2023.
• The 5-year median for Cash & Equivalents is $4.9 million (2024), against an average of $5.6 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 96.95% in 2023, then soared 1298.15% in 2024.
• TuHURA Biosciences' Cash & Equivalents stood at $4.9 million in 2022, then decreased by 24.8% to $3.7 million in 2023, then surged by 245.35% to $12.7 million in 2024, then sank by 71.4% to $3.6 million in 2025, then surged by 74.04% to $6.3 million in 2026.
• Business Quant data shows HURA's Cash & Equivalents at $6.3 million in Q1 2026, $3.6 million in Q4 2025, and $2.7 million in Q3 2025.